Mirum Pharmaceuticals Inc. - notizie pubblicate 221 - letture 2.957
MIRUM PHARMACEUTICALS INC.
Current Report - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
As filed with the securities and exchange commission on march 9, 2023 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-8 registr ...
MIRUM PHARMACEUTICALS INC.
Annual Report for Fiscal Year Ending --12-31, 2022 (Form 10-K)
United states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act of 193 ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Form 8-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer mirum pharmaceutical ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates - Form 8-K
Mirum pharmaceuticals announces preliminary unaudited livmarli 2022 net revenue and provides corporate updates - $76 million in total revenue and $74 million net product sales anti ...
MIRUM PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced the appointment of lon cardon, ph.d., fmedsci, to its board of directors where he ...
MIRUM PHARMACEUTICALS INC.
Current Report - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
- first and only medication approved in both the u.s. and europe to treat cholestatic pruritus in patients with alagille syndrome. - approval supported by more than six years of li ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on december 9, 2022, the compensation committee of mirum's board of directors ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti